---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Expected outcomes of therapy"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Expected outcomes of therapy. Topics: Pooled effect of psilocybin-assisted therapy in meta-analyses of randomized trials; Within-group change in psilocybin, SSRI, and esketamine trials; Relative effect compared with escitalopram in a network meta-analysis; Phase 2b trial: response, remission, and sustained response after a single 25 mg dose; 7 further topics. 11 evidence topics quoted from 17 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/expected-outcomes-of-therapy"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Expected outcomes of therapy

<a id="heading-2.2.2.7"></a>

## 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

### Pooled effect of psilocybin-assisted therapy in meta-analyses of randomized trials

> “The pooled SMD for 1-week between-group change in depression ratings was -0.72 [95% CI, -0.95 to -0.49; I2 = 17%; 5 RCTs; n = 403], favouring PAT; results were similar at days 2, 14, and 42.”
> “The response [RR = 3.42; 95% CI, 2.35-4.97; I2 = 0%; 4 RCTs; n = 373] and remission [RR = 3.66; 95% CI, 2.26-5.92; I2 = 0%; 4 RCTs; n = 373] rates also favored PAT.”

Source: [Menon et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39627679/)

> “The meta-analysis included 9 studies (pooled n = 596) and yielded a large effect size in favour of psilocybin (SMD = -0.78; p<0.001).”

Source: [Haikazian et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37844352/)

> “In major depressive disorder (MDD), psilocybin/ayahuasca/LSD reduced depressive symptoms (k = 8; SMD=-0.62 [-0.97; -0.28]; I2=55 %; GRADE=very low).”

Source: [Højlund et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41205366/)

<a id="topic-2.2.2.7-2"></a>

### Within-group change in psilocybin, SSRI, and esketamine trials

> “Pretreatment to posttreatment SMCs (SEMs) were 1.21 (0.15) for psilocybin, 1.28 (0.06) for SSRIs, and 1.43 (0.15) for esketamine and were 0.50 (0.15), 1.00 (0.08), and 1.12 (0.17) for their respective control treatments.”

Source: [Hieronymus et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12311713/)

<a id="topic-2.2.2.7-3"></a>

### Relative effect compared with escitalopram in a network meta-analysis

> “The relative effect of high dose psilocybin was larger than escitalopram at 10 mg (4.66 (95% credible interval 1.36 to 7.74)) and 20 mg (4.69 (1.64 to 7.54)).”

Source: [Hsu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11337322/)

<a id="topic-2.2.2.7-4"></a>

### Phase 2b trial: response, remission, and sustained response after a single 25 mg dose

> “In the 25-mg group, the incidences of response and remission at 3 weeks, but not sustained response at 12 weeks, were generally supportive of the primary results.”
> “Larger and longer trials, including comparison with existing treatments, are required to determine the efficacy and safety of psilocybin for this disorder.”

Source: [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/)

<a id="topic-2.2.2.7-5"></a>

### Durability after a single dose over 52 weeks

> “For all COMP 001 patients (n = 233), median time to depressive event was greater for the 25 mg group (92 days) compared to the 10 mg (83 days) and 1 mg (62 days) groups, with the majority of participants having had a depressive event by Week 12 (25 mg n = 37/75, 10 mg n = 38/79, 1 mg n = 44/75).”

Source: [Goodwin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40047545/)

<a id="topic-2.2.2.7-6"></a>

### Company-reported response, remission, and durability with retreatment

> “for all participants in Part C who received a 25 mg dose, strong response and remission rates were observed with 40%-45% responders and approximately 30% remitters across all timepoints in the 6 weeks post the Part C dose”

Source: [COMPASS Pathways COMP005 52-week release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-New-52-Week-Topline-Open-Label-Data-from-Phase-3-COMP005-Trial-Demonstrates-Additional-Benefit-from-Another-COMP360-Dose-in-Part-C-Extending-Durability-Out-to-1-Year/default.aspx)

> “Remarkable durability sustained through at least 6 months with only 1 or 2 additional doses after initial dose”
> “39% of participants in 25mg arm achieved a clinically meaningful reduction in MADRS at Week 6”
> “Clinically meaningful reduction in MADRS defined as a >25% reduction from baseline in MADRS total score at Week 6”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-2.2.2.7-7"></a>

### Independent phase 2b trial in treatment-resistant depression with an active placebo

> “Response rates on the primary end point were 17.0% in the group receiving psilocybin, 25 mg; 12.5% in the group receiving psilocybin, 5 mg; and 10.6% in the group receiving nicotinamide.”
> “In this randomized clinical trial, psilocybin, 25 mg, with adjunct psychotherapy, was associated with a clinically meaningful reduction in depressive symptoms in individuals with TRD, although findings did not show a significant effect on the primary outcome.”

Source: [Mertens et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13000742/)

<a id="topic-2.2.2.7-8"></a>

### Real-world outcomes outside controlled trials

> “Response and remission rates were 33.3% and 22.2% (MADRS), and 27.8% and 27.8% (BDI).”
> “Psilocybin was associated with a clinically meaningful reduction in depressive symptoms, with response and remission rates below those reported in previous trials.”

Source: [Jungwirth et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13453954/)

<a id="topic-2.2.2.7-9"></a>

### Long-term outcomes in veterans with severe treatment resistance

> “At Month 12, 40 % maintained response and 30 % maintained remission.”
> “However, the antidepressant effects began to wane at 6 months, and then more substantially after 9 months, although these increases in MADRS did not reach statistical significance.”

Source: [Ellis et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40499827/)

<a id="topic-2.2.2.7-10"></a>

### Regulatory statement on the evidence for durability and retreatment

> “Endurance of effect needs to be demonstrated.”
> “The experience and the available information on the sustainability of the action and the long-term effects, both desirable and undesirable of psychedelics and the efficacy of re-treatment are very limited.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

<a id="topic-2.2.2.7-11"></a>

### Expected outcomes with further conventional treatment steps or usual care

> “The QIDS-SR(16) remission rates were 36.8%, 30.6%, 13.7%, and 13.0% for the first, second, third, and fourth acute treatment steps, respectively.”
> “Overall, those who required more treatment steps had higher relapse rates during the naturalistic follow-up phase.”

Source: [Rush et al. (2006b)](https://pubmed.ncbi.nlm.nih.gov/17074942/)

> “The 12- and 24-month IDS-SR-30 response rates were 11.6% (13/112) and 18.4% (19/103), respectively.”
> “The 12- and 24-month IDS-SR-30 remission rates were 3.6% (4/112) and 7.8% (8/103), respectively.”

Source: [Dunner et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16841617/)

> “In the short term, TRD was highly recurrent with as many as 80% of those requiring multiple treatments relapsing within a year of achieving remission.”

Source: [Fekadu et al. (2009a)](https://pubmed.ncbi.nlm.nih.gov/19007996/)

> “The registry results indicate that the adjunctive VNS group had better clinical outcomes than the treatment-as-usual group, including a significantly higher 5-year cumulative response rate (67.6% compared with 40.9%) and a significantly higher remission rate (cumulative first-time remitters, 43.3% compared with 25.7%).”

Source: [Aaronson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28359201/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
